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INTRODUCTION 
 
Allograft rejection remains one of the major barriers to 
the long-term survival of the graft. More potent immuno- 
 
suppressive drugs and better histocompatibility between 
recipients and donors have altered the characteristics of 
allograft rejection. The risk of rejection within 1 year 
after kidney transplantation has declined to less than 
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Allograft rejection after renal transplantation remains a challenge to overcome. Interleukin (IL)-21, a cytokine 
with pleiotropic effects, maintains immune homeostasis post-transplantation. Here, we report higher levels of 
IL-21 in kidney transplant recipients with non-rejection (NR) than in recipients with T cell-mediated rejection 
(TCMR, P < 0.001) and antibody-mediated rejection (ABMR, P = 0.005). We observed a negative correlation 
between IL-21 and creatinine (Cr) levels (P = 0.016). The receiving operating characteristic (ROC) curve showed 
a promising diagnostic value of IL-21 to identify acute rejection with an area under the curve (AUC) of 0.822 (P < 
0.001). In contrast, exogenous administration of IL-21 accelerated acute rejection in a comparative translational 
kidney transplant (KT) mouse model. Reduced IL-21 levels in the peripheral blood were observed in KT mice 
after IL-21 injection. Further analysis revealed that increased IL-21 levels in the spleen induced proliferation of 
CD4+ T cells and CD19+ B cells after IL-21 treatment. Our findings suggest a critical function of IL-21 in kidney 
transplantation and the potential involvement of the IL-21/IL-21R pathway in acute rejection management. 
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15% [1]. However, the overall graft survival rates have 
still not improved due to the intractability of rejection 
[2]. Based on different clinicopathologies, rejection 
could be divided into T cell-mediated rejection (TCMR) 
and antibody-mediated rejection (ABMR) [1]. Patients 
with emerging rejection face an increased risk of graft 
failure, especially ABMR [3, 4]. 
 
Failure of immunosuppression and activation of the 
immune system against the allograft in recipients are 
majorly responsible for its rejection [1, 5]. The 
involvement of innate and adaptive immunity in TCMR 
and ABMR has been demonstrated by numerous 
clinical and animal studies [6–8]. Apart from the signals 
transduced by exogenous antigens and costimulatory 
molecules, cytokines secreted by immune cells, 
identified as “signal 3”, can activate the immune 
system, particularly T and B cells [9, 10]. Interleukin 
(IL)-21 is an important “signal 3” molecule that exerts 
its effects on T and B cells via autocrine and paracrine 
signaling. 
 
IL-21 is a proinflammatory cytokine involved in several 
immune dysfunction diseases. It is one of the main 
cytokines secreted by T follicular helper (Tfh) cells [11, 
12], which stimulate the differentiation of B cells into 
antibody-secreting plasma cells and have been reported 
to be involved in autoimmune disorders [13]. Weinstein 
et al. revealed the successive secretion pattern of IL-21 
and IL-4 by Tfh cells in germinal centers (GCs) using a 
double reporter mouse model [14] and highlighted the 
involvement of IL-21 in T and B cell crosstalk. 
Moreover, genome-wide association studies and animal 
studies have demonstrated a high expression of IL-21 in 
patients with autoimmune diseases, such as systemic 
lupus erythematosus [15, 16], rheumatoid arthritis [17], 
type 1 diabetes [18], and celiac disease [19]. The study 
of early onset of inflammatory bowel disease in patients 
deficient for IL-21 [20] has advanced the understanding 
of IL-21 as a proinflammatory cytokine. 
 
Increased levels of IL-21 in hyperplastic follicles were 
observed in a rhesus macaque kidney transplant model 
with ABMR [9]. The antagonist of IL-21 receptor (IL-
21R) was reported to block B cell differentiation [21]. 
Another study reported that the blocking of IL-21R 
ameliorated allograft rejection in a mouse skin 
transplant model [22]. Further, the role of IL-21 in 
immune tolerance in kidney transplant recipients is 
dependent on granzyme B (GZMB)+ B cells [23]. 
 
Previous studies have primarily focused on the effect of 
IL-21R blocking on transplantation or its in vitro 
effects. In the present study, we demonstrated the 
involvement of IL-21 in acute rejection after kidney 
transplantation. A unique cytokine profile was 
identified in patients with or without acute rejection 
after kidney transplantation. Surprisingly, higher levels 
of IL-21, accompanied by a comparable class switching 
rate of antibodies, were closely related with a stable 
immune status in patients after transplantation. To 
further directly investigate the function of IL-21 in 
maintaining a stable immune status, we generated a 
mouse model of kidney transplant (KT) with tail vein 
injection of exogenous IL-21. Intriguingly, histo-
pathological analysis revealed emerging acute rejection 
with an increased number of B cells after injection of 
exogenous IL-21. We believe that IL-21 can serve as a 






The demographic characteristics of different subgroups 
are summarized in Table 1. There was no difference 
among non-rejection (NR), TCMR, and ABMR cohorts 
regarding the donor-associated parameters, recipient’s 
age, primary kidney disease, dialysis, delayed graft 
function (DGF) rate, or HLA-mismatch (HLA-MM). 
Considerable differences in recipient’s gender (P = 
0.025) and induction (P = 0.001) were noted among the 
three cohorts. 
 
Higher peripheral blood IL-21 levels in stable 
transplant recipients 
 
The serum cytokine levels of recipients with or without 
acute rejection after kidney transplantation were 
measured using the Luminex assay. Levels of major 
proinflammatory cytokines, such as IL-2, IL-4, and IL-6 
(Figure 1A–1C), were slightly higher in acute rejection 
patients than in immune stable patients after kidney 
transplantation. Unexpectedly, the levels of IL-21, 
which is widely considered as a driving factor of GC B 
cell differentiation, were lower in acute rejection 
patients (11.02±0.29 pg/mL) than in immune stable 
patients (18.21±2.00 pg/mL, P < 0.001) (Figure 1G). 
Similarly, the circulating levels of interferon (IFN)-γ in 
acute rejection patients (13.18±2.02 pg/mL) were lower 
than in immune stable patients (29.41±6.59 pg/mL, P = 
0.012) (Figure 1I). Comparable levels of IL-10, IL-12, 
IL-17, IL-27, and tumor necrosis factor (TNF)-α (Figure 
1D–1F, 1H, and 1J) were observed between recipients 
with and without acute rejection. 
 
Distinct circulating cytokine levels in different types 
of rejection 
 
To further characterize and compare acute rejection 
subgroups, we divided the acute rejection cohort into 
 
www.aging-us.com 18398 AGING 











Donor associated parameters 
Age (years) 43.47±2.66 45.33±1.90 45.39±2.18 45.13±4.12 0.844 0.162 
Serum creatinine (mol/L) 92.36±11.48 99.19±12.98 101.03±14.62 92.75±29.97 0.892 0.286 
Donor type (DCD/LD) 19/11 22/14 19/9 3/5 0.291 0.853 
Donor sex(M/F) 22/8 24/12 19/9 5/3 0.807 0.557 
Recipients associated parameters 
Age (year) 41.27±1.88 36.94±1.79 38.00±2.08 33.25±3.38 0.511 0.791 
Sex (M/F) 10/20 22/14 16/12 6/2 0.054 0.025 
Kidney primary disease 0.697 0.466 
  Chronic kidney disease 25 25 20 5  
  IgA nephropathy  1 1 1 0  
  Lupus nephritis 0 1 1 0  
  Polycystic kidney disease  0 3 2 1  
  Diabetic nephropathy 0 1 1 0  
  Others 4 5 3 2  
Dialysis 0.495 0.480 
  Hemodialysis 20 20 14 6  
  Peritoneal dialysis 10 15 13 2  
  None 0 1 1 0  
DGF 1/29 31/5 5/23 0/8 0.100 0.137 
Induction 0.004 0.001 
  Simulect 9 19 13 6  
  ATG 5 13 11 0  
  Rituximab 0 1 1 2  
  None 16 3 3 0  
HLA-MM 2.63±0.23 2.61±0.22 2.68±0.27 2.38±0.26 0.837 0.924 
Stable creatinine 92.36±11.48 149.03±16.04 138.75±10.48 185.00±34.18 0.011 0.324 
Highest creatinine 92.36±11.48 248.25±24.37 235.75±25.80 292.00±63.42 <0.001 0.004 
DSA 0 8 0 8 0.006 <0.001 
Time of rejection NA 575.14±114.03 440.57±103.28 1046.13±336.15 NA NA 
NR, no rejection; AR, acute rejection; TCMR, T cell mediated rejection; ABMR, antibody mediated rejection; DGF, delayed 
graft function; ATG, anti-thymocyte globulin; HLA-MM, HLA-mismatch; DSA, donor specific antibody; Pa, P value represents 
the difference between NR and AR; Pb, P value represents the difference between NR, TCMR, and ABMR, using one-way 
ANOVA. 
 
TCMR and ABMR cohorts based on the histological 
evidence provided by Banff in 2017 [24]. We found that 
serum IL-2 levels were higher in the ABMR cohort than 
in the NR (P = 0.014) or TCMR (P = 0.016) cohort 
(Figure 2A). By contrast, serum levels of IL-4, IL-6 
(Figure 2B and 2C), IL-12, IL-27, and TNF-α 
(Supplementary Figure 1A–1C) showed no detectable 
difference among the three cohorts. The IL-21 levels in 
the NR cohort were higher than in both TCMR 
(10.98±0.35 pg/mL, P < 0.001) and ABMR (11.15±0.56 
pg/mL, P = 0.008) cohorts (Figure 2F). However, no 
difference was found between the two rejection 
subgroups. Elevated levels of IL-10 were present in 
ABMR cohort, and slightly reduced levels of IL-17 and 
IFN-γ were present in the TCMR cohort (Figure 2D, 2E 
and Supplementary Figure 1D). 
Cytokines are characterized as “signal 3” in T and B 
cell crosstalk, which promotes B cell differentiation, 
maturation, and class switching. The class switching 
rate of B cells was measured by detecting the levels of 
serum immunoglobulins. No difference was found in 
the levels of IgM and IgG1-3 in the three cohorts 
(Figure 3A–3C). The circulating levels of IgG4 were 
high in the ABMR cohort (P = 0.044 vs. NR cohort and 
P = 0.012 vs. TCMR cohort) (Figure 3D). 
 
Serum IL-21 levels negatively correlate with 
allograft function 
 
The correlation between circulating cytokine levels and 
allograft function was analyzed (Supplementary Table 
1). Linear regression analysis revealed a good 
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Figure 1. Higher peripheral blood IL-21 levels in stable transplant recipients. Absolute concentration (pg/mL) of serum IL-2, IL-4, IL-
6, IL-10, IL-12, IL-17, IL-21, IL-27, IFN-γ, and TNF-α (A–J) in recipients with (n = 36) and without (n = 30) active rejection after kidney 
transplantation. Red dash dot line represents the mean value. *P < 0.05 and **P < 0.01 compared with NR cohorts. IL, interleukin; IFN, 




Figure 2. Distinct circulating cytokine levels in different types of rejection. Serum levels of IL-2, IL-4, IL-6, IL-10, IL-17, and IL-21 (A–F) 
in patients in NR (n = 30), TCMR (n = 28) and ABMR (n = 8) cohorts were measured before anti-rejection therapy. Dash dot line represents the 
mean value. *P < 0.05, **P < 0.01, and ***P < 0.001. IL, interleukin; ABMR, antibody-mediated rejection; NR, non-rejection; TCMR, T cell-
mediated rejection. 
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correlation of serum IL-21 (ρ = −0.018, P = 0.016) and 
TNF-α (ρ = 0.006, P < 0.001) (Figure 4A and 4B) levels 
with serum creatinine (Cr), indicating that circulating 
cytokines could be a potential biomarker for monitoring 
renal dysfunction. The diagnostic capacity of IL-21 and 
TNF-α in distinguishing allograft rejection was measured 
using the receiver operating characteristic (ROC) curve. 
The area under the curve (AUC) for serum IL-21 levels 
was 0.822 (P < 0.001), with sensitivity and specificity of 
72.22% and 80%, respectively, and a cut-off value of 
11.47 pg/mL (Figure 4C). TNF-α exhibited less 
diagnostic capacity in rejection diagnosis with an AUC of 
0.636 (P = 0.059) (Figure 4D). 
 
Exogenous IL-21 promotes allograft rejection in 
mice 
 
To explore the function of IL-21 in transplant 
immunobiology, we generated KT mice with tail vein 
injection of exogenous IL-21 on days 0, 2, 4, and 6 
post-transplantation (Figure 5A). Hematoxylin and 
eosin (HE), periodic acid-Schiff (PAS), and Masson’s 
staining revealed enhanced infiltration of inflammatory 
cytokines and fibrosis in the allograft that worsened 
with IL-21 administration (Figure 5B). Next, the 
cytokine levels in the transplanted kidney were 
estimated; similar to the inflammatory infiltration, the 
expression of proinflammatory cytokines such as IFN-γ 
(P < 0.001 vs. control group and P = 0.008 vs. KT 
group) and TNF-α (P = 0.011 vs. control group) was 
upregulated (Figure 5C). The IL-21 (P < 0.001 vs. 
control group) and IL-4 (P = 0.011 vs. control group) 
levels in the transplanted kidney reduced (Figure 5D). 
No difference was found in the levels of IL-10, IL-6, 
and IL-17 in the transplanted kidney among the three 
groups (Figure 5E). 
 
Next, we evaluated the histopathology of the allograft. 
A heavy deposit of linear C4d in peritubular capillaries 
(P = 0.016 vs. control group) after IL-21 injection 
(Figure 6A and 6B) was observed. More severe 
allograft injury, including glomerulitis, tubulitis, and 
interstitial inflammation, was observed in KT mice with 
IL-21 treatment (Figure 6C, 6D, and 6E). Peritubular 
capillary and intimal arteritis showed no difference 
(Figure 6F and 6G). The donor-specific antibody (DSA) 
titers in the kidney recipients were measured by flow 
cytometry. Higher DSA titers were observed after  
IL-21 administration (P = 0.008 vs. control group) 




Figure 3. No significant difference in antibody class switching between NR and active rejection cohorts was observed. (A, B) 
Levels of IgM and IgG1-4 in NR (n =30) and rejection (n = 35) groups. (C, D) Levels of IgM and IgG1-4 in NR (n =30), TCMR (n = 28), and ABMR 
(n = 7) cohorts. The dash dot line represents the mean value. The difference among the three subgroups was analyzed using one-way ANOVA. 
*P < 0.05. ABMR, antibody-mediated rejection; ANOVA, analysis of variance; NR, non-rejection; TCMR, T cell-mediated rejection. 
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Exogenous IL-21 alters cytokine and IL-21R 
expression in mice after kidney transplantation 
 
The cytokine levels in the peripheral blood and spleen of 
KT mice were measured on the day mice were sacrificed. 
Interestingly, the peripheral IL-21 levels in mice after 
administration of exogenous IL-21 were lower than in 
mice injected with phosphate-buffered saline (PBS) (P = 
0.004) and control groups (P < 0.001) (Figure 7A). 
Moreover, the IL-6 levels increased after IL-21 treatment, 
but no major difference was found (Figure 7B). No 
difference was found among the levels of IL-2, IL-4, IL-
10, and IL-17 (Figure 7A and 7B), whereas an increased 
level of inflammatory cytokine TNF-α was observed (P = 
0.011 vs. control group) (Supplementary Figure 3A). A 
substantial increase in IL-21 levels in the spleen was 
observed after administration of exogenous IL-21 (P = 
0.040 vs. PBS injection) (Figure 7D), with a higher 
expression of IL-21R (P = 0.021 vs. PBS injection and P 
= 0.011 vs. control group) (Figure 7C and Supplementary 
Figure 3C–3E). Furthermore, compared with the other 
two groups, IL-10 levels were higher in the KT group (P 
= 0.018 vs. control group, P = 0.014 vs. IL-21+KT group) 
(Figure 7E). 
Exogenous IL-21 induces B and T cell proliferation 
 
Flow cytometry was performed to analyze B and T cells 
in the peripheral blood and spleen. After kidney 
transplantation, the number of B cells slightly increased, 
and the number was higher after IL-21 stimulation both 
in the peripheral blood (P < 0.001 vs. control group, P = 
0.008 vs. KT group) and the spleen (P = 0.004 vs. 
control group) (Figure 8A, 8C). Furthermore, the 
number of CD4+ T cells in the peripheral blood steadily 
increased in kidney transplanted mice administered IL-
21 than in those administered PBS (P = 0.003) (Figure 
8B, 8D). The number of CD4+ T cells was more 





In the present study, we measured the serum levels of 
IL-21 in acute rejection patients post kidney 
transplantation and assessed its function in a mouse KT 
model. Reduced serum levels of IL-21 were detected in 
both TCMR and ABMR cohorts as compared to 




Figure 4. Serum IL-21 levels correlate with allograft function. Correlation of serum IL-21 and TNF-α levels with serum Cr levels  
(A, B). The ROC curves of IL-21 and TNF-α to investigate their ability to distinguish between rejection and NR recipients (C, D). Cr, creatinine; 
IL, interleukin; NR, non-rejection; ROC, receiver operating characteristic; TNF, tumor necrosis factor. 
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Figure 5. Exogenous IL-21 promotes inflammatory infiltration in the allograft. C57BL/6 mice received renal allografts from Balb/c 
mice. Kidney recipients were injected recombinant murine IL-21 (10 μg in 100 μL PBS; n = 9) or 100 μL PBS (n = 7) in the tail vein on days 0, 2, 
4, and 6 after transplantation (A). Blank control (n = 3) of mice without transplantation received tail vein injection of PBS simultaneously. All 
animals were sacrificed 7 days post-transplantation. Histologic evaluation of kidney allografts from Control, KT, and IL-21+KT recipients on 
day 7 post-transplantation stained with (B) H&E, PAS, and Masson’s stains (scale bar: 100μm). Levels of (C) IFN-γ and TNF, (D) IL-21, IL-2, and 
IL-4, (E) IL-10, IL-6, and IL-17 in the transplanted kidney of KT subgroups and primary kidney of Control are shown. Values represent mean 
(±SEM). *P < 0.05, **P < 0.01, and ***P < 0.001. H&E, hematoxylin and eosin; IL, interleukin; PAS, periodic acid–Schiff; PBS, phosphate-
buffered saline; KT, kidney transplant; SEM, standard error of the mean. 
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negatively correlated with allograft function, showing a 
promising diagnostic value with an AUC of 0.822 (P < 
0.001). Interestingly, no difference in class switching was 
found. Administration of exogenous IL-21 accelerated 
allograft rejection in KT mice, accompanied by reduced 
levels of IL-21 in the peripheral blood and enrichment of 
IL-21 in the spleen. Further analysis revealed IL-21-
induced enhanced proliferation of T and B cells in the 
spleen resulting in acute humoral rejection. 
 
IL-21 is a cytokine with pleiotropic effects; it maintains 
the immune homeostasis including in patients after solid 
organ transplantation [25]. It is identified as the most 
potent plasma cell inducer in vitro [26]. IL-21 activates 
both Tfh cells [15, 27] and B cells in GCs via autocrine 
and paracrine signaling. Similarly, elevated levels of IL-
21 in the GC of ABMR recipients suggest its possible 
function in the GC during the onset of active rejection 
[9]. Blocking of IL-21 activity ameliorated the graft-
versus-host disease after hematopoietic stem cell 
transplantation [28]. 
 
Intriguingly, IL-21 can also mediate immuno-
suppressive effect. Studies have reported that IL-21 
induces apoptosis of immunocytes by upregulating the 
expression of transcription factor Bcl-2 [29, 30]. 
Chesneau et al. recently reported the function of IL-21-
dependent GZMB+ B cells in maintaining immune 
tolerance in kidney transplant recipients. Moreover, 
they observed elevated secretion of IL-21 by T cells 
after stimulation by B cells in tolerant recipients [23]. 
Their findings were mainly based on in vitro 
experiments and lacked the study of serum cytokine 
levels in patients. In the present study, we measured the 
cytokine levels in kidney transplant recipients. Elevated 




Figure 6. Exogenous IL-21 promotes active kidney rejection in mice. (A and B) Expression of C4d in the allograft (scale bar: 250μm). 
Histopathology scores of glomerulities, tubulitis, I, PTC, and V (C–G) of the kidney allografts from Control, KT, and IL-21+KT recipients. Values 
represent mean (±SEM). *P < 0.05, **P < 0.01, and ***P < 0.001. PTC, peritubular capillaritis; I, interstitial inflammation; V, intimal arteritis; 
IL, interleukin; KT, kidney transplant; SEM, standard error of the mean. 
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immune status. Serum IL-21 levels negatively 
correlated with serum Cr levels, whereas with an AUC 
of 0.822 (P < 0.001), IL-21 measurement did not 
outperform the diagnostic capacity of Cr (AUC: 0.989, 
P < 0.001). 
 
IL-21 is involved in antibody class switching of B cells 
in both human and mouse systems to activate the 
humoral response. The IgG production level was 
reported to be slightly lower in IL-21R-deficient mice 
[31]. However, the blocking of both IL-4 and IL-21R 
severely impaired the IgG response [31]. In addition, we 
evaluated the rate of antibody class switching in patients 
post kidney transplantation; it was largely intact when 
acute rejection occurred. Because the serum IL-4 levels 
were comparable among NR, TCMR, and ABMR 
cohorts, this result was expected. 
 
Patients with stable graft function for more than 5 years 
were enrolled in the NR cohort. In contrast, the average 
time of rejection in the total rejection group was 
575.14±114.03 days. NR and rejection groups were not 
matched with respect to the time from transplantation 
due to insufficient follow-up durations to define NR. 
However, no correlation was observed between the time 
of rejection and cytokine and antibody levels (data not 
presented). 
IL-21 is a well-conserved gene [32]. The distribution of 
its effector IL-21R and the downstream signaling 
pathways, through which it regulates the differentiation 
and functions of lymphoid cells responsible for humoral 
response, are similar in human and mice [33]. Hence, 
we established a KT mouse model to further directly 
address the role of IL-21 in kidney transplantation. 
Exogenous IL-21 was injected into KT mice to mimic 
the serum IL-21 levels in immune stable patients. 
However, unexpectedly, the injection of exogenous IL-
21 induced enhanced inflammatory infiltration, C4d 
deposit, and allograft injury including glomerulitis, 
tubulitis, and interstitial inflammation in the 
transplanted kidney. These findings suggest that 
exogenous IL-21 induced a higher rate of rejection 
instead of maintaining immune tolerance, a finding 
considerably different from that reported by previous 
studies [9, 22]. 
 
IL-21 exerts its effect on a variety of immune cells via 
the IL-21R to promote cell differentiation and 
maturation [33]. It is involved in the generation and 
differentiation of Tfh cells through an autocrine loop 
and amplifies its secretion [15, 27]. Moreover, it 
augments the proliferation, maturation, and differen-
tiation of B cells by upregulating transcription factors 




Figure 7. Exogenous IL-21 alters cytokine and IL-21R expression in mice after kidney transplantation. The level of IL-21, IL-2, and 
IL-4, and IL-10, IL-6, and IL-17A in the peripheral blood (A and B) and spleen (D and E) on day 7 post-transplantation was measured by CBA. 
(C) Histologic evaluation of IL-21R expression in the spleen of subgroups. Values represent mean (±SEM). *P < 0.05, **P < 0.01, and ***P < 
0.001. CBA, cytometric bead array; IL, interleukin; SEM, standard error of the mean. 
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the present study, the administration of IL-21 led to the 
corresponding increased IL-21R expression in the 
spleen. The upregulated expression of IL-21R allows 
IL-21 to perform its growth factor-like functions via the 
IL-21/IL-21R signaling pathway. Furthermore, flow 
cytometry was used to analyze the proportion of 
immune cells in the peripheral blood and spleen of KT 
mice after IL-21 injection. An increase in the number of 
B cells in both peripheral blood and spleen was 
observed, accompanied by an elevated number of CD4+ 
T cells in the peripheral blood. 
 
Tfh cells are the primary source of serum IL-21, 
whereas the ability of Tfh subsets to produce IL-21 is 
variable. Recent studies have reported that Tfh cells can 
be further divided into GC Tfh cells and peripheral Tfh 
cells based on different locations [35]. The IL-21 
secretion ability of GC Tfh cells is extremely low such 
that little or no induction of IL-21 in antigen-specific 
GC Tfh cells was detected in macaque studies [36–38], 
whereas the peripheral Tfh cells have been reported to 
secrete high levels of cytokines such as IL-21 [39]. We 
detected decreased serum IL-21 levels in mice after KT 
despite the administration of exogenous IL-21, which 
was similar to the serum level of IL-21 in patients with 
acute rejection after KT, with a notably higher level of 
IL-21 in the spleen observed after IL-21 injection. 
Besouw et al. recently reported a correlation between 
increased donor-specific IL-21-producing cells, 
especially circulating Tfh cells, and kidney graft 
rejection [40]. Accumulation of Tfh cells in follicular-




Figure 8. Exogenous IL-21 induces B cell and T cell proliferation. Flow cytometry analysis to measure CD19+ B (A) and CD4+ T (B) 
lymphocytes in the peripheral blood and spleen of recipients and controls. Distribution of proportions of CD4+ T cells (C) and CD19+ B cells (D) 
of total lymphocytes on day 7 post-transplantation. Boxes and whiskers represent minimum to maximum of all the data. **P < 0.01 and ***P 
< 0.001 one-way ANOVA. ANOVA, analysis of variance; IL, interleukin. 
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by Graav et al. [41]. This could be attributed to the fact 
that during acute rejection onsets, peripheral IL-21-
producing Tfh cells enter into the spleen and allograft, 
activating T and B cell proliferation and maturation by 
secreting IL-21 in the GC or follicular-like structures, 
leading to acute rejection. 
 
The present study had certain limitations. First, the 
number of patients enrolled in this study was relatively 
low because of the low incidence rate of acute rejection 
in our kidney disease center. As healthy volunteers do 
not have alloantigens or take immunosuppressants, the 
immune status of such population is considerably 
different from that of kidney transplant recipients. 
Although our study could not include healthy controls 
due to their unwillingness to provide samples, we 
believe the NR cohort used as the disease control should 
be sufficient for studying transplant immunology 
changes in allograft rejection. This is because the 
immune status of the NR cohort is considerably closer 
to that of rejection cohorts. Second, the present study 
did not provide biopsy information of patients with 
stable allograft function because patients refused to 
undergo biopsy due to a Chinese tradition. Third, 
although we studied the critical function of IL-21 in 
kidney transplantation, the interpretation of results still 
requires more clinical evidence. 
 
In conclusion, we observed distinctly lower levels of 
serum IL-21 in acute rejection patients, with a 
diagnostic and therapeutic implication of IL-21 from a 
precision medicine perspective. The mouse KT model 
proved useful in conducting in vivo studies of IL-21 
biology. The injection of exogenous IL-21 triggered 
allograft rejection in kidney transplantation mice and 
resulted in enrichment of IL-21 in the spleen. Flow 
cytometry study revealed the proliferation of CD4+ T 
and CD19+ B cells in the peripheral blood and spleen 
when rejection occurred. These findings suggest the 
involvement of IL-21 in transplant immunobiology, 
highlighting its therapeutic potential in acute rejection. 
 




The study was approved by the Research Ethics 
Committee of The First Affiliated Hospital, College of 
Medicine, Zhejiang University (Hangzhou, China; 
approval number: 2016-512). All patients provided 
written informed consent. From September 2017 to 
September 2018, a total of 66 peripheral blood samples 
were collected from 66 patients after kidney 
transplantation, of which 30 were NR, 28 were acute 
TCMR, and 8 were active ABMR. Of the 28 patients in 
the TCMR group, 12 patients belonged to grade IA, two 
patients belonged to grade IB, 13 patients belonged to 
grade IIA, and 1 patient belonged to grade IIB. Patients 
with stable allograft function (creatinemia < 150 
mmol/L and proteinuria < 1g/24 h [23]), negative panel 
reactive antibodies, and no BK virus infection for more 
than 5 years post transplantation were enrolled into the 
NR cohort. Patients with histological confirmation of 
acute rejection were enrolled in the rejection cohort, 
which was further divided into TCMR and ABMR 
according to the Banff 2017 criterion [24]. Exclusion 
criteria included acute infection, use of glucocorticoids, 
or anti-thymocyte globulin (ATG) pulse in 3 months. 
The characteristics of different subgroups are 
summarized in Table 1. 
 
The peripheral blood samples of patients in the NR 
cohorts were collected during their routine follow-up 
investigations. The peripheral blood samples of patients 
in the acute rejection cohort were collected before renal 
biopsy and anti-rejection treatment. Histopathology was 
conducted by two experienced pathologists in our 
hospital.  
 
Detection of serum cytokine levels and isotype class 
switching in serum 
 
Serum levels of cytokines IL-2, IL-4, IL-6, IL-10, IL-
12, IL-17, IL-21, IL-27, IFN-γ, and TNF-α, and IgM 
and IgG subsets were measured by the multiplex bead 
immunoassay (HGAMMAG-301K-05, Millipore for 
cytokine detection; LXSAHM-10, R&D system for 
antibody detection, Shanghai Universal Biotech Co., 
Ltd) according to the manufacturer’s instructions. 
Briefly, the beads with standards and samples were 
incubated for 1 h at room temperature. The wells were 
washed with wash buffer and incubated with primary 
antibodies for 30 min. Afterward, the coated beads were 
incubated with biotinylated antibodies for 30 min. The 





All protocols involving animals were approved by the 
Institutional Animal Care and Utilization Committee of 
The First Affiliated Hospital, College of Medicine, 
Zhejiang University. The C57BL/6 and Balb/c mice 
were purchased from the Laboratory Animal Center of 
Zhejiang University. All mice were housed in sterile 
microisolator cages. Eight-week-old male mice were 
used in all experiments. 
 
Kidney transplantation and treatment 
 
The left kidney from Balb/c mice was transplanted 
into C57BL/6 mice with anastomosis to the inferior 
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vena cava and the recipient abdominal aorta, ureter 
anastomosis to the bladder as previously described 
[42]. The right kidney remained intact. Recombinant 
murine IL-21 (BMS6021, eBioscience; 10 μg in 100 
μL PBS) (n = 9) [43] or 100 μL PBS (n = 7) was 
administered by tail vein injection into the recipients 
at days 0, 2, 4, and 6 after transplantation (Figure 5A). 
PBS was administered by tail vein injection into mice 
without transplantation (blank control, n = 3) 





Primary renal, spleen, and renal allograft tissue cross-
sections were fixed in 10% formalin and embedded in 
paraffin. Five µm sections were cut with a Leica 
CM1900 cryomicrotome (Leica Biosystems Division of 
Leica Microsystems Inc.). The sections underwent 
H&E, PAS, and Masson's staining for histological 
evaluation. Immunochemistry staining was performed 
following the manufacturer’s protocol. Briefly, sections 
were deparaffinized by successively washing them with 
xylene, 100% and 95% ethanol, and distilled water. 
After antigen unmasking and blocking, the sections 
were incubated with anti-C4d antibody (HP8033; 
Hycult Biotech, USA) or anti-IL21R antibody (ab5980; 
Abcam, UK) overnight at 4°C. The rabbit-specific 
HRP/AEC IHC Detection Kit Micro-polymer (Abcam, 
UK) was used to visualize the stained sections, followed 
by staining with diaminobenzidine and counterstaining 
with hematoxylin. The acute humoral rejection was 
confirmed by the presence of DSA, linear C4d staining 
in peritubular capillaries, and histologic evidence of 
graft injury [44]. A well-experienced pathologist scored 
the histopathologic characteristics of rejection, 
including tubulitis, glomerulitis, interstitial 
inflammation, intimal arteritis, and peritubular 
capillaritis according to the Banff lesion scores [45]. 





The serum DSA titers in kidney transplant mice were 
measured using the previously reported method [46]. In 
brief, after pretreatment with mice Fc blocker, the cell 
suspensions of kidney donor spleen were incubated with 
diluted recipient serum collected on day 7 post kidney 
transplantation. The cells were washed using PBS thrice 
and subsequently incubated with anti-mouse IgG 
(Abcam) for 15 min on ice. The unbound antibody was 
washed away with PBS and the cells were analyzed by 
flow cytometry. The mean channel fluorescence of each 
sample was calculated using the FlowJo software (Tree 
Star Inc.) and reported as a titer. 
Cytometric bead array 
 
Cytokines from the peripheral blood, spleen, and 
transplanted kidney were isolated as previously 
described [47]. Cytokine levels in the peripheral blood 
and spleen of mice after kidney transplantation were 
measured by cytometric bead array (CBA). The spleen 
and kidney tissues were mechanically homogenized, 
and the supernatants were collected. The Mouse Soluble 
Protein Master Buffer Kit and the appropriate CBA flex 
sets Mouse Th1/Th2/Th17 Cytokine Kit (BD 
Biosciences) were used to perform CBA analysis. 
 
As per the manufacturer’s protocol, the supernatants 
were mixed with capture beads after 2× dilution in the 
diluent. Flow cytometry samples were run on 
ACSCantoII, LSRFortessa (BD Biosciences), and the 
data were analyzed using the FlowJo software (Tree 
Star Inc.). The median fluorescence intensity on beads 
was used for statistical analysis. A standard curve was 
used to extrapolate the protein concentrations. 
 
Isolation of cells from spleen, kidneys, and graft 
 
The tissue was gently dissociated using the gentleMACS 
Dissociator (Miltenyi Biotec) in the PBS/bovine serum 
albumin (BSA)- ethylene diamine tetraacetic acid 
(EDTA) buffer. The buffer was prepared by mixing the 
BSA stock solution with autoMACS Rinsing Solution 
containing EDTA at a ratio of 1:20 (Miltenyi Biotec). The 
MACS Pre-Separation Filters (Miltenyi Biotec) were used 
to ensure that the dissociated tissue samples were free of 





Peripheral blood was collected in sodium heparin tubes. 
Next, the peripheral blood mononuclear cells (PBMCs) 
were isolated using Ficoll (GE Healthcare) gradient 
centrifugation on the same day. CD4+ T cells and 
CD19+ B cells were analyzed by Flow cytometry. In 
brief, the PBMCs were labeled with anti-CD4 and anti-
CD19 antibodies for 30 min at room temperature in the 
dark. Gates for CD4+ T cells and CD19+ B cells were 
determined based on the staining with anti-mice CD4 
and anti-mice CD19 antibodies (BioLegend). The 
number of CD4+ T cells and CD19+ B cells in the 
peripheral blood and spleen of mice after KT was 
determined by FACSCalibur (BD Biosciences). FlowJo 




All statistical analyses were performed using the 
GraphPad Prism 8 (La Jolla). Continuous data are 
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presented as mean±standard error of the mean (SEM), 
whereas frequencies are presented as proportions. One-
way analysis of variance (ANOVA) was performed for 
multiple group comparisons. The Mann-Whitney U test 
was performed for unpaired t test. For categorical 
covariates, Chi-square tests were used to generate P-
values. Linear regression was performed to determine 
correlations. All presented P-values were calculated 
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Supplementary Figure 1. Serum cytokine levels in transplant recipients. Serum levels of IL-12, IL-27, TNF-α, and IFN-γ (A−D) in 
patients with NR (n = 30), TCMR (n = 28), and ABMR (n = 8) cohorts were measured before the anti-rejection therapy. Red dash dot line 
represents the mean value. *P < 0.05 compared with NR cohorts. ABMR, antibody-mediated rejection; IFN, interferon; IL, interleukin; TNF, 





Supplementary Figure 2. Higher DSA titers were observed after IL-21 administration. **P < 0.01 compared with the control. DSA, 
donor-specific antibody; IL, interleukin; KT, kidney transplant. 
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Supplementary Figure 3. Exogenous IL-21 alters cytokine and IL-21R expression in mice after kidney transplantation. The 
levels of IFN-γ and TNF-α in (A) the peripheral blood and (B) spleen on day 7 post-transplantation were measured by CBA. The expression of 
IL-21R in the spleen of (C) control, (D) KT, and (E) IL-21+KT mice on day 7 post-transplantation. Values represent the mean (±SEM). **P < 0.01 
compared with the control. CBA, cytometric bead array; IFN, interferon; IL, interleukin; KT, kidney transplant; SEM, standard error of the 
mean; TNF, tumor necrosis factor. 
  
 




Supplementary Table 1. Correlation between serum cytokine levels and creatinine levels at rejection onset. 
 
IL-2 IL-4 IL-6 IL-10 IL-12 IL-17 IL-21 IL-27 IFN-γ TNF-α 
Slope 0.04035 0.004171 0.002605 0.002559 0.001074 −0.0005405 −0.01824 0.1259 −0.03793 0.006161 
P-value 0.5044 0.8906 0.1431 0.1787 0.9055 0.5304 0.0157 0.7046 0.1285 <0.0001 
 
